Why the study?
Does ACEI or ARB therapy reduce LV mass and cardiovascular events in patients receiving hemodialysis?
Does ACEI or ARB therapy reduce LV mass and cardiovascular events in patients receiving hemodialysis?
In hemodialysis patients, ACEI or ARB therapy reduces LV mass but current evidence does not show a significant reduction in fatal and nonfatal cardiovascular events.
Does not support ACEI/ARB for CV event reduction in hemodialysis despite LV mass benefit; leaves open need for definitive trials.
Treatment with an ACEI or ARB reduced LV mass in patients receiving HD. However, their use was not associated with a statistically significant reduction in the risk of fatal and nonfatal CV events. Larger, high-quality trials in the HD population are required to determine if the effects of ACEI or ARB therapy on LV mass translate into decreased CV morbidity and mortality.
No takes yet. Share an insight, caveat, or question.
Tai et al. (2010) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: